Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.76 EUR
Change Today +0.001 / 0.04%
Volume 13.8K
WL6 On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

wilex ag (WL6) Snapshot

Open
€2.92
Previous Close
€2.76
Day High
€3.10
Day Low
€2.76
52 Week High
03/31/14 - €5.89
52 Week Low
01/6/15 - €1.71
Market Cap
25.6M
Average Volume 10 Days
25.0K
EPS TTM
€-0.96
Shares Outstanding
9.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WILEX AG (WL6)

Related News

No related news articles were found.

wilex ag (WL6) Related Businessweek News

No Related Businessweek News Found

wilex ag (WL6) Details

WILEX AG, a biopharmaceutical company, is focuses on the research, development, manufacture, approval, and marketing of drugs and diagnostic agents in the field of oncology. The company operates in three segments: Therapeutics (Rx), Diagnostics (Dx), and Customer Specific Research (Cx). Its primary product candidates based on antibodies and small-molecule compounds comprise REDECTANE, an imaging diagnostic candidate that has completed Phase III clinical trials for the treatment of renal masses; and MESUPRON, which has completed Phase clinical trials for the treatment of pancreatic and breast cancer. The company also provides customer specific contract services related to a technology platform for therapeutic antibody drug conjugates; and preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. WILEX AG has a strategic alliance with UCB Pharma S.A. (UCB) to develop UCB’s preclinical oncological portfolio comprising two small-molecule programs and three antibody programs. The company was formerly known as WILEX Biotechnology GmbH and changed its name to WILEX AG in February 2001. WILEX AG was founded in 1997 and is headquartered in Munich, Germany.

Founded in 1997

wilex ag (WL6) Top Compensated Officers

Chief Financial Officer and Member of the Exe...
Total Annual Compensation: €287.2K
Head of Research & Development and Member of ...
Total Annual Compensation: €245.8K
Compensation as of Fiscal Year 2013.

wilex ag (WL6) Key Developments

Wilex AG Reports Earnings Results for the Year Ended November 30, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Wilex AG reported earnings results for the year ended November 30, 2014. The Group generated sales revenue and other income totaling EUR 5.0 million compared to EUR 19.1 million a year ago. The net loss for the year was EUR 5.7 million compared to EUR 5.0 million a year ago. The company posted sales revenue of EUR 3.6 million in the 2014 financial year, down 73% from the previous year of EUR 13.3 million. At EUR 1.4 million, other income was down substantially compared to the previous year of EUR 5.8 million. Operating loss was EUR 5.6 million compared to EUR 5.0 million year ago. Loss per share was EUR 0.73 compared to EUR 0.64 a year ago. The company expects to generate between EUR 4.0 million and EUR 6.0 million in revenue and other income in the 2015 financial year. Loss before interest and taxes (LBIT) in the 2015 financial year are expected to be between EUR 2.0 million and EUR 5.0 million.

Wilex AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 03:00 PM

Wilex AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 03:00 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Wilex AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-25-2014

Wilex AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-25-2014 . Venue: Maritim Hotel, Theodor-Heuss-Allee 3, 60486 Frankfurt am Main, Germany.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WL6:GR €2.76 EUR +0.001

WL6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WL6.
View Industry Companies
 

Industry Analysis

WL6

Industry Average

Valuation WL6 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WILEX AG, please visit www.wilex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.